Reuven Yeganeh Sells 530,000 Shares of BiomX (NYSEAMERICAN:PHGE) Stock

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 530,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total value of $2,650,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Reuven Yeganeh also recently made the following trade(s):

• On Monday, March 16th, Reuven Yeganeh sold 450,000 shares of BiomX stock. The stock was sold at an average price of $5.00, for a total value of $2,250,000.00.

BiomX Trading Down 1.2%

Shares of NYSEAMERICAN PHGE opened at $4.98 on Friday. BiomX Inc. has a 52 week low of $1.50 and a 52 week high of $14.71. The company’s 50-day moving average price is $4.98 and its 200 day moving average price is $6.34. The stock has a market cap of $7.92 million, a price-to-earnings ratio of -0.20 and a beta of 1.68.

BiomX (NYSEAMERICAN:PHGE) last released its quarterly earnings results on Thursday, February 19th. The company reported $6.99 earnings per share (EPS) for the quarter. As a group, research analysts expect that BiomX Inc. will post -2.77 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. bought a new position in BiomX Inc. (NYSEAMERICAN:PHGE) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX at the end of the most recent quarter. 40.57% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a report on Monday, March 9th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, BiomX currently has an average rating of “Hold” and a consensus price target of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.